More articles about Disease Areas

The collaborative study includes testing urine samples from patients who have an increased risk for complicated urinary tract infections.

The deal comes as the firms try — for the second time — to close a merger that had previously failed to gain necessary approval from Rosetta shareholders.

The firm's Guardant360 assay will be used first to test patients for ERBB2 mutations, then guide patients to a variety of treatment arms.

The company has received a subpoena from HHS' OIG as part of an investigation into possible improper billing of its hereditary cancer tests to Medicare and Medicaid.

Natera and Qiagen have signed a 10-year agreement to develop cell-free DNA assays for use on Qiagen's GeneReader next-generation sequencing system.

Researchers saw clinically actionable heart disease mutations in fewer than 5 percent of sudden infant death syndrome cases interrogated by molecular autopsy.

Through its large network of ambulatory labs, the university's pathology and lab medicine department is evaluating a BioFire rapid diagnostic test for the flu. 

The 4,000-participant study will use a digital enrollment platform and will provide free genetic testing as well as support from doctors and genetics experts.

The group will work with hospitals to recruit patients with a genetic history of Parkinson's to test for mutations in LRRK2 and GBA, as well as offer genetic counseling.

The researchers conducted a genome-wide association study and other analyses using about 47,000 research participants from 23andMe.

Researchers used a capture Hi-C strategy to identify candidate target genes and pathways at dozens of loci previously linked to breast cancer susceptibility.

The assay correlates shortened telomere lengths in patients of different ages to potential risks for inherited diseases, such as bone marrow failure syndrome and liver cancer.

A proteomic and targeted exome sequencing study of diffuse-type gastric cancer led to proteomic subtypes with distinct mutation, survival, and potential treatment patterns.

The companies will develop an assay and software package for Thermo's cancer research product portfolio.

The latest version of the nucleic acid detection platform uses three CRISPR enzymes, making it more sensitive and capable of smaller quantitative measurements.

The company plans to grow its business based on the FDA approval and preliminary national coverage determination for its FoundationOne CDx test last year. 

The investment bank based the upgrade on potential for growth in the installed base of Quidel's immunoassay and molecular instruments, among other factors.

The collaborators aim to show that Cytox' VariaTect SNP profiling array and an associated algorithm can effectively predict the presence of Alzheimer's pathology.

The company fell short of Wall Street expectations on the top and bottom lines and said it plans on making some significant changes for 2018, including shutting down its liquid biopsy testing. 

Interpace said that its two thyroid tests are now covered for over 280 million patients nationwide including Medicare, Medicare Advantage, and national and regional health plans.


The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.